NCT03587844View on ClinicalTrials.gov

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

July 3, 2018

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Mycosis FungoidesLymphomatoid PapulosisSezary Syndrome
Interventions
DRUG

brentuximab vedotin

MF/SS Brentuximab vedotin 0.9 mg/kg 0R 1.2 mg/kg.

DRUG

brentuximab vedotin

LyP Brentuximab vedotin 0.9 mg/kg2

DRUG

brentuximab vedotin

MF/SS prior brentuximab vedotin-Brentuximab vedotin dose to be determined from Cohort 1

Trial Locations (8)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

10604

RECRUITING

Memorial Sloan Kettering Westchester, Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau, Uniondale

11725

RECRUITING

Memorial Sloan Kettering Commack, Commack

94305-5408

RECRUITING

Stanford University Medical Center, Stanford

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth, Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen, Montvale

All Listed Sponsors
collaborator

Seagen Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER